CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at…
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Firm"), a late-stage biotechnology firm growing Leronlimab, a CCR5 antagonist with potential for a number of therapeutic indications, reminded buyers that Dr. Scott Kelly,…